Announcement on behalf of OBIGEN of not Distributing Dividends of 2023

1.Date of the board of directors resolution:2024/03/20 2.Type and monetary amount of dividend distribution:The Board of Directors of OBIGEN resolved not to distribute dividends of 2023. 3.Any other matters that …

Announcement on behalf of OBIGEN that the BOD resolved to issue 2024 employee stock options and the subscription rules.

1.Date of the board of directors resolution:2024/03/20 2.Issue period:Issued within two years since the date of approval of Board of Directors; issued at once or in tranches depending on actual …

Announcement on behalf of OBIGEN that the BOD resolved to convene the 2024 Annual General Shareholders’ Meeting

1.Date of the board of directors resolution:2024/03/20 2.General shareholders’ meeting date:2024/06/19 3.General shareholders’ meeting location: Conference room of OBI Pharma, Inc. (6th Floor, No. 508, Section 7, Zhongxiao East Road, …

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform. OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential …

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

OBI Pharma is excited to announce that Dr. Ming-Tain Lai, Chief Scientific Officer, has been invited to present an oral presentation at the upcoming 14th World ADC conference in London, United Kingdom. This …

OBI announces the termination of OBI-3424 Phase II trial

Following a strategic portfolio review, the Board of Directors of OBI Pharma, Inc. (4174) has decided to terminate the OBI-3424-001 trial today (March 11, 2024), while continuing the collaboration of …

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers

1.Date of the board of directors resolution:2024/03/11 2.Name and title of the managerial officer with permission to engage in competitive conduct: Heidi Wang/ CEO Ming-Tain Lai/ Chief Scientific Officer Colin …

Announcement of 2023 Consolidated Financial Statements were approved by the Board of Directors

1.Date of the board of directors submitted or approved:2024/03/11 2.Date of the audit committee approved:2024/03/08 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): …

The Company’s Board of Directors resolved to convene the 2024 Annual General Shareholders’ Meeting

1.Date of the board of directors resolution:2024/03/11 2.General shareholders’ meeting date:2024/06/17 3.General shareholders’ meeting location: Masterlink Securities Education and Training Center (11F., No.97, Sec. 2, Dunhua S. Rd., Taipei City) …

Announcement of not Distributing Dividends in 2023

1.Date of the board of directors resolution:2024/03/11 2.Year or quarter which dividends belong to :2023 3.Period which dividends belong to:2023/1/1 to 2023/12/31 4.Appropriations of earnings in cash dividends to shareholders …